Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
15 août 2022 16h08 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
11 août 2022 07h00 HE
|
Fulcrum Therapeutics, Inc.
Presented initial data from Phase 1b trial in sickle cell disease (SCD), which demonstrate rapid and robust increases in hemoglobin F (HbF); supports proof-of-concept that FTX-6058 is a novel oral HbF...
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
04 août 2022 08h07 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 août 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 juil. 2022 08h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 15, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Departure of Chief Medical Officer
11 juil. 2022 17h00 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
05 juil. 2022 07h00 HE
|
Fulcrum Therapeutics, Inc.
– REACH is the first Phase 3 trial for this rare, progressive, and debilitating muscular disease –– Losmapimod is an oral small molecule that has the potential to be the first therapy to treat...
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 juin 2022 16h02 HE
|
Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
10 juin 2022 07h02 HE
|
Fulcrum Therapeutics, Inc.
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF...
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
12 mai 2022 17h08 HE
|
Fulcrum Therapeutics, Inc.
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from...